PGAM1 and neoplasm: These therapeutic innovations are synergistically supported by advanced functional imaging techniques, particularly 18F-fluorothymidine (18F-FLT) PET, which enables non-invasive real-time monitoring of PGAM1 inhibitor target engagement and subsequent DNA synthesis modulation, facilitating precision dose optimization in heterogeneous tumor ecosystems.